Nanoparticle News and Research

RSS

In nanotechnology, a particle is defined as a small object that behaves as a whole unit in terms of its transport and properties. It is further classified according to size: in terms of diameter, fine particles cover a range between 100 and 2500 nanometers, while ultrafine particles, on the other hand, are sized between 1 and 100 nanometers.

Scientists discover a new method to produce gold nanoparticles

Gold nanoparticles, tiny pieces of gold so small that they can't be seen by the naked eye, are used in electronics, healthcare products and as pharmaceuticals to fight cancer. Despite their positive uses, the process to make the nanoparticles requires dangerous and extremely toxic chemicals. While the nanotechnology industry is expected to produce large quantities of nanoparticles in the near future, researchers have been worried about the environmental impact of the global nanotechnological revolution.

30 Nov 2010

USPTO, EPO issue key patents for Tekmira's LNP technology

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today that the United States Patent & Trademark Office (USPTO) and the European Patent Office (EPO) have issued key patents covering elements of Tekmira's leading lipid nanoparticle (LNP) technology, which is used to deliver nucleic acid therapeutics, including small interfering RNA (siRNA).

23 Nov 2010

Nanoparticles in everyday products can affect lungs: Study

Tiny particles used in a range of everyday products from computers to shampoo can adversely affect the lungs in very different ways, a study has shown.

18 Nov 2010

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today presented additional interim data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The data were presented at the Chemotherapy Foundation Symposium being held in New York City.

11 Nov 2010

Kylin receives $250,000 IRS award to advance pRNAi nanoparticle cancer treatment research

Officials of Kylin Therapeutics Inc. announces that they received a therapeutic discovery project grant from the U.S. Internal Revenue Service that will advance the company's pRNAi nanoparticle cancer treatment research.

11 Nov 2010

Contraceptive, antiviral gel using bee venom wins 2010 Gates Foundation grant

A vaginal gel that affords both contraception and HIV protection using nanoparticles that carry bee venom is one of the bold, unconventional ideas that won a 2010 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation.

10 Nov 2010

NCI awards $4 million for UNM's cancer nanotechnology partnership with Sandia Labs

The National Cancer Institute recently announced two five-year awards totaling nearly $4 million for a partnership between the University of New Mexico Cancer Center and Sandia National Laboratories. One $1.95 million grant will fund the creation of a joint Cancer Nanotechnology Platform Partnership, and another $1.8 million grant will pay for a new Cancer Nanotechnology Training Center to train a new generation of multidisciplinary scientists.

10 Nov 2010

bitop includes first patient in Ectoin inhalation solution clinical trial for inflammation and airway obstruction

bitop AG, a biotech company specializing in the development of Ectoin®-containing medical devices, announced the inclusion of the first patient into a clinical trial on the Ectoin inhalation solution in patients with inflammation and airway obstruction.

8 Nov 2010

Novel technology using quantum dots increases drug uptake in lung injury

Researchers at the University at Buffalo have developed a novel technology using quantum dots that is expected to have major implications for research and treatment of tuberculosis, as well as other inflammatory lung diseases.

2 Nov 2010

New nanoparticle deodorant has antibacterial and anti-odor properties

Scientists are reporting development of a new approach for dealing with offensive household and other odors one that doesn't simply mask odors like today's room fresheners, but eliminates them at the source. Their research found that a deodorant made from nanoparticles hundreds of times smaller than peach fuzz eliminates odors up to twice as effectively as today's gold standard.

30 Oct 2010

Malvern Zetasizer Nano used to characterize environmentally responsive nanoparticles

The rapid, real-time measurement capabilities of the Zetasizer Nano system from Malvern Panalytical have enabled quantified nanoscale characterization of the environmental sensitivity of novel solubilization nanoparticles.

From Malvern Panalytical 28 Oct 2010

Techulon signs exclusive license with Virginia Tech to market new theranostic transfection reagent

Techulon™ Inc., an early stage life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new theranostic transfection reagent. This new traceable reagent complements Techulon's currently marketed Glyocofect™ transfection platform and expands the company's offering in an $800 million market that is steadily growing at 15% annually.

26 Oct 2010

Techulon signs license with Virginia Tech Intellectual Properties to market DNA delivery platform

Techulon Inc., a life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new, traceable DNA delivery platform created to deliver genetic medicine to cells while carrying a beacon so scientists can follow its progress.

22 Oct 2010

Altogen Biosystems releases PEG-Liposome siRNA In Vivo Transfection Kit

Altogen Biosystems announced the release of its second generation of in vivo RNAi transfection reagent in the company's popular in vivo delivery product line: PEG-Liposome siRNA In Vivo Transfection Kit. This reagent is also compatible for in vivo transfection of other negatively charged molecules – RNA, DNA, and small proteins.

22 Oct 2010

Dicerna secures $4 million in second closing of Series B equity financing

Dicerna Pharmaceuticals, Inc. a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology and Dicer Substrate siRNA (DsiRNA) molecules, today announced a second closing of its Series B equity financing, securing an additional $4 million and bringing the total capital raised in this round to $29 million.

22 Oct 2010

Lubricin reduces wear to bone cartilage

A team of researchers in North Carolina has discovered that lubricin, a synovial fluid glycoprotein, reduces wear to bone cartilage. This result, which has implications for the treatment of sufferers of osteoarthritis, will be presented today at the AVS 57th International Symposium & Exhibition, taking place this week at the Albuquerque Convention Center in New Mexico.

21 Oct 2010

Access submits additional patent applications for Cobalamin-mediated oral drug delivery technology

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has submitted additional patent applications, covering its Cobalamin-mediated oral drug delivery technology formulations of many global top-100 injectable drugs, as a result of the growing interest surrounding the company's proprietary oral delivery technology.

21 Oct 2010

Researchers to test nanoparticle-based theranostics for pancreatic cancer treatment

Researchers from Rice University's Laboratory for Nanophotonics (LANP), the radiology department at Baylor College of Medicine (BCM) and the University of Texas MD Anderson Cancer Center are preparing to test a combined approach for diagnosing and treating pancreatic cancer with a specially engineered nanoparticle.

19 Oct 2010

Silver studded bacteria could help treat common cold and flu

Finally scientists may have found a potential cure for common cold. They have found “silver bullets” in yogurt that could destroy viruses and provide a cure for the flu and common cold.

18 Oct 2010

NIH awards contract to develop nanotechnology tools for atherosclerosis treatment

Georgia Tech and Emory University have received a five-year $14.6 million contract from the National Institutes of Health (NIH) to continue the development of nanotechnology and biomolecular engineering tools and methodologies for detecting and treating atherosclerosis.

5 Oct 2010

Nanoparticle News and Research

Further Reading

Scientists discover a new method to produce gold nanoparticles

USPTO, EPO issue key patents for Tekmira's LNP technology

Nanoparticles in everyday products can affect lungs: Study

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Kylin receives $250,000 IRS award to advance pRNAi nanoparticle cancer treatment research

Contraceptive, antiviral gel using bee venom wins 2010 Gates Foundation grant

NCI awards $4 million for UNM's cancer nanotechnology partnership with Sandia Labs

bitop includes first patient in Ectoin inhalation solution clinical trial for inflammation and airway obstruction

Novel technology using quantum dots increases drug uptake in lung injury

New nanoparticle deodorant has antibacterial and anti-odor properties

Malvern Zetasizer Nano used to characterize environmentally responsive nanoparticles

Techulon signs exclusive license with Virginia Tech to market new theranostic transfection reagent

Techulon signs license with Virginia Tech Intellectual Properties to market DNA delivery platform

Altogen Biosystems releases PEG-Liposome siRNA In Vivo Transfection Kit

Dicerna secures $4 million in second closing of Series B equity financing

Lubricin reduces wear to bone cartilage

Access submits additional patent applications for Cobalamin-mediated oral drug delivery technology

Researchers to test nanoparticle-based theranostics for pancreatic cancer treatment

Silver studded bacteria could help treat common cold and flu

NIH awards contract to develop nanotechnology tools for atherosclerosis treatment

How to solve the hidden bottleneck in lipid nanoparticle development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo